CLYM Climb Bio, Inc.
$9.57▲ +8.63%
Healthcare
Other
After hours
$9.60▲ +0.31%
Oct 27, 4:00 PM ET
Volume 3.90M
Avg Volume (10D) 1.14M
Key Metrics & Fundamentals
Market Cap
$549.66M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.64 - 18.33
% vs 50 MA
-26.51%
% vs 200 MA
-7.00%
RSI-14
37.9
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.59
Free Cash Flow
-$10.81M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.33M
COGS
–
Operating Exp
$15.36M
Operating Income
-$15.36M
EBIT
-$15.36M
Pretax Income
-$13.50M
Net Income
-$13.50M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
GlobeNewswire · Oct 24, 2026 7:30 PM ET
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
GlobeNewswire · Oct 23, 2026 4:01 PM ET
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
Investing.com · Oct 20, 2026 11:14 AM ET
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Zacks · Oct 20, 2026 8:40 AM ET
Deutsche Bank Initiates Coverage on Climb Bio With Buy Rating, $28 Price Target
MT Newswires · Oct 20, 2026 7:12 AM ET
Climb Bio's Upcoming Data Updates on CLYM116, Budoprutug to Be 'More Incremental,' RBC Says
MT Newswires · Oct 13, 2026 11:26 AM ET
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
GlobeNewswire · Oct 2, 2026 9:30 AM ET
Raymond James Updates Healthcare Top Picks for October
Investing.com · Oct 1, 2026 4:26 PM ET
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Investor's Business Daily · Sep 23, 2026 4:12 PM ET
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating
MT Newswires · Sep 8, 2026 9:24 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CLYM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.